Accordingly, these results indicated that AIM2 signaling might contribute to an unbalanced immune response in COVID-19 patients characterized by enhanced inflammatory responses, reduced antiviral signaling, potentially leading to tissue damage or disease severity. This evidence concerns the gene AIM2 and COVID-19.